Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Allergan is a good example of how many mergers and acquisitions over a very short period of time created a large, international company.
WuXi AppTec will acquire a global clinical-stage contract research company, ResearchPoint Global, of Austin, Texas.
Pfizer has increased its stake in Rhythm Pharmaceuticals.
Sachem Head Capital Management is pushing for that company to break up into small entities in order to increase shareholder value.
Amneal and Impax are combining into a new entity that is expected to have the fifth largest generics business in the United States.
The approval has made Flexion an even bigger target of acquisition rumors.
In a filing with the SEC,Orexigen indicated that it may not have enough funds to continue operating.
